Self-regulating osmotic gastroretentive drug delivery systems
Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane. The rapid swelling of the composition to a size greater than the size of the pyloric sphincter is due to the presence of an osmogen, adequate membrane permeability that provides for fast generation of CO 2 from a gas-generating agent(s), and adequate membrane elasticity that provides for rapid expansion of the membrane. The hydrated core, especially the polyethylene oxide in the push layer, and the permeable elastic membrane with an orifice (1) provide extended release of the active pharmaceutical agent, and (2) maintain the dosage form at a size suitable for gastric retention. The self-regulating composition collapses, or breaks into pieces, after releasing at least about 80% of the drug from the composition.
1. An osmotic, floating gastroretentive dosage form comprising:
a) a multilayer core comprising:
(i) a pull layer containing an active pharmaceutical agent, an acid, and a gas generating agent; and
(ii) a push layer, and
b) a permeable elastic membrane surrounding the multilayer core, wherein the permeable elastic membrane contains at least one orifice,
wherein the permeable elastic membrane comprises a copolymer of ethyl acrylate, methyl methacrylate, and trimethylamminoethyl methacrylate chloride (1:2:0.2); and at least one plasticizer,
wherein the copolymer is present in an amount of from about 70% to about 90% w/w of the combined weight of the plasticizer and the copolymer,
wherein the orifice in the permeable elastic membrane is in fluid communication with the pull layer,
wherein the gas generating agent is present in an amount of from about 10 wt % to about 50 wt % of the pull layer weight, and
wherein the dosage form, when coming in contact with a dissolution medium simulating gastric conditions, swells in about 60 minutes or less to a swollen state that prevents its passage through pyloric sphincter of a human.
2. The dosage form of claim 1 , wherein the plasticizer is selected from the group consisting of triethyl citrate, triacetin, polyethylene glycol, propylene glycol, dibutyl sebacate, and mixtures thereof.
3. The dosage form of claim 1 , wherein the gas generating agent is sodium bicarbonate, calcium carbonate, or a mixture thereof.
4. The dosage form of claim 1 , wherein the acid is selected from the group consisting of succinic acid, citric acid, acetic acid, malic acid, tartaric acid, boric acid, and mixtures thereof.
5. The dosage form of claim 1 , wherein both the pull layer and the push layer further comprise swellable water-soluble polymers.
6. The dosage form of claim 5 , wherein the swellable water-soluble polymer in the push layer is a polyethylene oxide polymer having an average molecular weight of greater than or equal to about 600,000 Da.
7. The dosage form of claim 6 , wherein the polyethylene oxide polymer has an average molecular weight of about 600,000 Da, about 700,000 Da, about 800,000 Da, about 900,000 Da, about 1,000,000 Da, about 2,000,000 Da, about 3,000,000 da, about 4,000,000 Da, about 5,000,000 Da, about 6,000,000 Da, about 7,000,000 Da, or any intermediate values therein.
8. The dosage form of claim 5 , wherein the swellable water-soluble polymer in the pull layer is a polyethylene oxide polymer having an average molecular weight of less than or equal to 1000,000 Da.
9. The dosage form of claim 8 , wherein the polyethylene oxide polymer has an average molecular weight of about 100,000 Da, about 200,000 Da, about 300,000 Da, about 400,000 Da, about 500,000 Da, about 600,000 Da, about 700,000 Da, about 800,000 Da, about 900,000 Da, or any intermediate values therein.
10. The dosage form of claim 1 , wherein the active pharmaceutical agent is a moderately soluble drug or a weakly soluble drug.
11. The dosage form of claim 1 , wherein the dosage form is an oval, modified oval, or capsule shaped, multilayer, gastroretentive tablet comprising a long axis and a short axis, wherein the long axis is from about 12 mm and to about 22 mm, and the short axis is from about 8 mm to about 11 mm.
12. The dosage form of claim 1 , wherein the push layer further comprises an osmogen selected from the group comprising sodium chloride, potassium chloride, potassium sulfate, lithium sulfate, sodium sulfate, lactose and sucrose combination, lactose and dextrose combination, sucrose, dextrose, mannitol, dibasic sodium phosphate, and combinations thereof.
13. An osmotic, floating gastroretentive dosage form comprising:
a) a multilayer core comprising:
(i) a pull layer containing an active pharmaceutical agent, an acid, and a gas generating agent; and
(ii) a push layer, and
b) a permeable elastic membrane surrounding the multilayer core, wherein the permeable elastic membrane contains at least one orifice,
wherein the permeable elastic membrane comprises a copolymer of ethyl acrylate, methyl methacrylate, and trimethylamminoethyl methacrylate chloride (1:2:0.2); and at least one plasticizer,
wherein the orifice in the permeable elastic membrane is in fluid communication with the pull layer,
wherein the gas generating agent is present in an amount of from about 10 wt % to about 50 wt % of the pull layer weight, and
wherein the dosage form, on coming in contact with gastric fluid, expands in 60 minutes or less to a size that prevents its passage through the pyloric sphincter.
14. The dosage form of claim 13 , wherein the copolymer is present in an amount of from about 70% to about 90% w/w of the combined weight of the plasticizer and the copolymer.
15. An osmotic, floating gastroretentive dosage form comprising:
a) a multilayer core comprising:
(i) a pull layer containing an active pharmaceutical agent, an acid, and a gas generating agent; and
(ii) a push layer, and
b) a permeable elastic membrane surrounding the multilayer core, wherein the permeable elastic membrane contains at least one orifice,
wherein the permeable elastic membrane comprises a copolymer of ethyl acrylate, methyl methacrylate, and trimethylamminoethyl methacrylate chloride (1:2:0.2); and at least one plasticizer,
wherein the orifice in the permeable elastic membrane is in fluid communication with the pull layer,
wherein the gas generating agent is present in an amount of from about 10 wt % to about 50 wt % of the pull layer weight, and
wherein the dosage form, on coming in contact with 200 ml a dissolution medium comprising pH 4.5 acetate buffer, exhibits a volume gain of about 100% in about 60 minutes or less.
16. The dosage form of claim 15 , wherein the copolymer is present in an amount of from about 70% to about 90% w/w of the combined weight of the plasticizer and the copolymer.